Biotechnology
Major breakthrough of Sanyou Biopharmaceuticals AI-STAL
SHANGHAI, May 18, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals announced today that its independently developed AI-STAL has undergone a significant upgrade, successfully achieving a qualitative leap from "molecular treasure trove" to "intelligent engine", marking the company's entry into a new ...
2026-05-18 22:00
397
Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial
- BBT002 is a next-generation, long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-5 - - Preliminary Phase 1 data demonstrated rapid, deep, and sustained effects on key biomarkers for at least 8 weeks following a single dose, including pSTAT6...
2026-05-18 21:15
743
Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
* Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®. * Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axill...
2026-05-18 21:00
810
Earendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)
WILMINGTON, Del., May 18, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced the successful completion of cohort 1 dosing in a phase I clinical trial for a novel biparatopic antibody targeting Thymic...
2026-05-18 19:00
924
Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate
Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B- Targeting Antibody Demonstrates Potential to Become a Best-in-Class Therapy for Obesity CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, May 17, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical compan...
2026-05-18 08:03
1189
WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index
SHANGHAI, May 17, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been selected for the 2026 Dow Jones Best-in-Class World Index (DJ BIC World Index, formerly Dow Jones Sustainability World Index), whic...
2026-05-18 08:00
1057
LOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma
SEOUL, South Korea, May 17, 2026 /PRNewswire/ -- LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic partn...
2026-05-18 08:00
1016
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
* RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerabilityto date. * Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors. MELBOURNE, Australia...
2026-05-15 22:25
7207
Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced solid tumor patients SYDNEY, May 15, 2026 /PRNewswire/ -- Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, today ...
2026-05-15 19:06
3344
Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
HONG KONG, May 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be presented as an oral presentation at the 2026 European ...
2026-05-15 15:43
2979
SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of 'SNB-101'
SEONGNAM, South Korea, May 14, 2026 /PRNewswire/ -- SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in its global Phase 1b/2 clinical trial evaluating SNB-101 (API: SN-38), a nanoparticle anticancer ag...
2026-05-15 07:03
2448
DeepQure Reports Encouraging Clinical Data from World's First Extravascular RDN System at AUA 2026
WASHINGTON, May 14, 2026 /PRNewswire/ -- DeepQure, a clinical-stage medical device company, announced the completion of its featured presentation at the American Urological Association (AUA) Innovation Nexus Forum, held during the AUA Annual Meeting. DeepQure was selected to present the clinical ...
2026-05-15 02:30
2258
OnCusp Therapeutics Appoints Anthony Kim as Chief Financial Officer
PRINCETON, N.J., May 14, 2026 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company developing differentiated oncology therapies designed to translate cutting-edge innovation into clinically meaningful outcomes for patients, today announced the appointment of Antho...
2026-05-14 21:00
2381
Origin Agritech to Hold Business Update & First Half Fiscal Year 2026 Earnings Conference Call on May 22 at 8 a.m. ET
BEIJING, May 14, 2026 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, will announce its financial results for the first half of fiscal year 2026 on Thursday, May 21. Origin will host a conference call on Friday, M...
2026-05-14 20:00
4703
EBT Medical and NinaMED Announce US$13.75M Financing to Advance Licensed NiNA System® for Overactive Bladder
* US$13.75M financing completed to accelerate clinical pathway and global commercialisation * Establishment of NinaMED Pty Ltd, a new Australian medtech company * NinaMED Pty Ltd secures a license from EBT Medical for exclusive global rights to NiNA System®, a non‑invasive, at‑home OAB thera...
2026-05-14 13:03
2232
METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceuticals
HONG KONG, May 13, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a tech-bio company focused on AI-powered nanodelivery innovation, today successfully listed on the Hong Kong Stock Exchange (HKEX), becoming the world's first publicly listed AI-powered drug delivery company and the first AI-powered...
2026-05-14 10:09
2830
Elabscience® Launches Self-Developed PolyHRP-Streptavidin Conjugate for Low-Abundance Biomarker Detection in ELISA
HOUSTON, May 13, 2026 /PRNewswire/ -- Elabscience® Bionovation Inc. ("Elabscience®" or "the Company") today announced the launch of its self-developed PolyHRP-Streptavidin conjugate, a signal amplification reagent designed to improve enzyme-linked immunosorbent assay (ELISA) sensitivity for low-...
2026-05-14 00:00
2736
Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
* The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialized solutions for payload-linkers. * This cutting-edge suite will significantly enhance the company's ability to support global payload-linke...
2026-05-13 22:45
3155
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included i...
2026-05-13 11:33
2533
Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China
CRANBURY, N.J. and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse Consulting Group ("DHCG" or "the Group"), a leader in strategic and oper...
2026-05-12 23:00
3973
Week's Top Stories
Most Reposted
Tonik Becomes the First Standalone Digital Bank in the Philippines to Achieve Profitability
[Picked up by 297 media titles]
2026-05-12 10:15
Visa amps up the music as Official Payment Partner for the Asia leg of The Weeknd's 'After Hours Til Dawn' Stadium Tour
[Picked up by 295 media titles]
2026-05-11 16:20
Avnet and HKSTP Invite Global Startups to New AI Hardware Launchpad
[Picked up by 292 media titles]
2026-05-12 10:00Hong Leong Bank Awarded Best Managed Bank in Malaysia by The Asian Banker, Group MD/CEO Kevin Lam Named Best Bank CEO in Malaysia
[Picked up by 288 media titles]
2026-05-15 17:00
Peach Blossoms Celebrates Three Massive Wins - Black Pearl Restaurant Guide 2026, Asia's 50 Best Restaurants 2026 Extended List and Tatler Best 20 Restaurants in Singapore 2026
[Picked up by 285 media titles]
2026-05-12 14:00
